Simplifying Global Compliance
ClinicalTrials.gov and the New Final Rule (42 CFR Part 11) - Webinar CD/Transcript
| Quantity Discounts | 1 - 2 $287.00 | 3 - 4 $258.00 | 5 - 6 $244.00 | 7 - 9 $230.00 | 10 - 9999 $215.00 |
ClinicalTrials.gov and the New Final Rule (42 CFR Part 11): What Strategic Decisions Do You Need to Consider?
Many trial operators are still scratching their heads. After reading and re-reading the 177 pages of 42 CFR Part 11, “Final Rule for Clinical Trials Registration and Results Information,” can you honestly say:
- You are certain you’re submitting everything it calls for?
- You are in compliance with all required timelines?
- You understand what changes under the final reg, and what remains the same?
If the answer is “no” — or even “maybe” — you’re not alone. This new final rule is full of changes large and small.
FDAnews is addressing the confusion with a new training session featuring a leading light of the FDA regulatory bar, Scott Cunningham Esq., translating the knottiest provisions of the final regulation into simple English. Here’s what you’ll discover:
- The four elements of an “applicable drug clinical trial,” and how the FDA will interpret what these words really mean
- Who must submit clinical trial results to ClinicalTrials.gov
- Clinical trial data submissions deadlines
- The enforcement landscape: What the FDA can do to police non-compliance, and when enforcement might start
- Deciphering the ClinicalTrials.gov “voluntary submissions” provisions
- Navigating provisions on “delayed submission” of results to ClinicalTrials.gov
- FDA proposals for release of de-identified data — current status
- And much more!
This training session gives you what you need to know — in just 90 minutes. Don’t risk sanctions for non-compliance. Get up to speed before the inspectors come around.
- Medical Affairs
- Clinical Operations
- Regulatory Affairs
- Publications Directors
- Clinical Trial Regulatory Directors
- Clinical Trial Information Disclosure Directors
- Global Clinical Safety and Pharmacovigilance Officers
Scott Cunningham Esq. is a partner in Covington & Burling’s San Francisco-based Food and Drug Practice Group, representing pharma, biotech, regenerative medicine, and medical device firms. His expertise covers the gamut of FDA regulatory issues, including new product development/approval, clinical trials, IRBs, Hatch-Waxman exclusivities, advertising/promotion, false claims compliance, orphan drugs, pediatric exclusivity, cGMP/manufacturing, import/export, controlled substances and SEC disclosure.
